hVIVO plc announce Phase 2b Influenza Field Study Contract

Highlights

·    hVIVO to enrol up to 1,000 healthy volunteers as part of a multicenter field study testing an influenza drug candidate, with hVIVO selected as the sole UK clinical site

·    Largest field study contract supporting a new income stream

·    Expected to improve staff utilisation and leverage in-house volunteer recruitment platform

·    Expansion of Plumbers Row outpatient unit to support future Phase II and Phase III field studies

hVIVO plc (Euronext / LON:HVO), a fast growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that it has been engaged for a Phase 2b field study assessing an influenza candidate. This contract is with a US company (‘the client’) and will commence later this year with hVIVO enrolling up to 1,000 healthy volunteers as part of a multicenter study with hVIVO being selected as the sole UK clinical site.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    X
    LinkedIn
    hVIVO plc

    More articles like this

    hVIVO plc

    hVIVO fast-tracks drug trials and draws big pharma in

    In a sector where timelines can stretch over decades and budgets run into billions, hVIVO is rewriting the rules—delivering clinical insight in a fraction of the time and attracting heavyweight pharmaceutical partners along the way. hVIVO